Profile data is unavailable for this security.
About the company
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
- Revenue in USD (TTM)0.00
- Net income in USD-3.11m
- Incorporated2007
- Employees2.00
- LocationBone Biologics Corp2 Burlington Woods Dr Ste 100BURLINGTON 01803-4551United StatesUSA
- Phone+1 (781) 552-4452
- Fax+1 (845) 818-3588
- Websitehttps://www.bonebiologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bluejay Diagnostics Inc | 0.00 | -20.07m | 1.90m | 7.00 | -- | 0.2164 | -- | -- | -134.42 | -134.42 | 0.00 | 9.01 | 0.00 | -- | -- | 0.00 | -103.46 | -70.71 | -124.04 | -82.92 | -- | -- | -- | -12,694.84 | -- | -- | 0.0028 | -- | -- | -- | -110.38 | -- | 119.51 | -- |
| Agentix Corp | 0.00 | -590.30k | 1.94m | -- | -- | -- | -- | -- | -0.0147 | -0.0147 | 0.00 | -0.0873 | 0.00 | -- | -- | -- | -735.53 | -- | -- | -- | -- | -- | -- | -- | -- | -11.76 | -- | -- | -- | -- | 3.09 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 2.15m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.20m | 30.00 | -- | -- | -- | 3.67 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| Clearside Biomedical, Inc | 3.33m | -26.00m | 2.20m | 32.00 | -- | -- | -- | 0.6621 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| InMed Pharmaceuticals Inc | 4.51m | -7.66m | 2.22m | 13.00 | -- | 0.2223 | -- | 0.4923 | -4.08 | -4.08 | 1.72 | 3.42 | 0.4577 | 3.09 | 20.23 | -- | -77.84 | -87.37 | -93.34 | -107.49 | 29.73 | -- | -170.07 | -356.16 | 5.30 | -- | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| Bone Biologics Corp | 0.00 | -3.11m | 2.26m | 2.00 | -- | 0.42 | -- | -- | -4.00 | -4.00 | 0.00 | 3.00 | 0.00 | -- | -- | 0.00 | -64.38 | -75.06 | -70.17 | -130.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 57.56 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -12.88m | 2.34m | 7.00 | -- | -- | -- | -- | -15.97 | -15.97 | 0.00 | -0.6301 | 0.00 | -- | -- | 0.00 | -343.49 | -- | -1,530.48 | -- | -- | -- | -- | -- | -- | -44.72 | -- | -- | -- | -- | -31.07 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 2.39m | 9.00 | -- | 0.7888 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.42m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 2.54m | 5.00 | -- | 0.4847 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 2.62m | 0.00 | -- | 10.44 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
Data as of Mar 03 2026. Currency figures normalised to Bone Biologics Corp's reporting currency: US Dollar USD
2.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DRW Securities LLCas of 31 Dec 2025 | 23.58k | 1.31% |
| Two Sigma Investments LPas of 31 Dec 2025 | 11.08k | 0.62% |
| Citadel Securities LLCas of 31 Dec 2025 | 10.84k | 0.60% |
| Tower Research Capital LLCas of 31 Dec 2025 | 3.38k | 0.19% |
| UBS Securities LLCas of 31 Dec 2025 | 1.95k | 0.11% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 230.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 31 Dec 2025 | 14.00 | 0.00% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 0.00 | 0.00% |
| Clear Street LLCas of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
